Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00301886
Other study ID # CDR0000463758
Secondary ID S0308U10CA037429
Status Withdrawn
Phase Phase 3
First received March 9, 2006
Last updated November 11, 2013
Start date May 2006
Est. completion date May 2006

Study information

Verified date November 2013
Source Southwest Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

RATIONALE: Zoledronate and ibandronate may prevent or help relieve bone pain and other symptoms caused by bone metastases. It is not yet known whether zoledronate is more effective than ibandronate in preventing bone problems caused by bone metastases due to breast cancer.

PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to ibandronate in preventing bone problems in women with stage IV breast cancer that has spread to the bone.


Description:

OBJECTIVES:

Primary

- Compare the efficacy of zoledronate vs ibandronate, in terms of preventing the occurrence of skeletal-related events (SRE) (e.g., fracture, spinal cord compression, radiotherapy or surgery for bone symptoms or events, or hypercalcemia ≥ grade 3), in women with stage IV breast cancer and bone metastases.

Secondary

- Compare the change in patient-reported measures of pain and use of analgesics in patients treated with these drugs.

- Compare the time to first clinically apparent SRE in patients treated with these drugs.

- Compare the toxicity of these drugs.

- Compare the changes in performance status and overall survival of patients treated with these drugs.

OUTLINE: This is a multicenter, randomized study. Patients are stratified according to hormone receptor status (estrogen receptor [ER] and progesterone receptor [PR] negative vs ER and/or PR positive) and current evidence of fracture (vertebral or nonvertebral) or spinal compression (yes vs no). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral ibandronate once daily on days 1-28.

- Arm II: Patients receive zoledronate IV over 15 minutes on day 1. In both arms, treatment repeats every 28 days for up to 18 courses in the absence of unacceptable toxicity.

Quality of life and pain are assessed at baseline, every 3 courses during study treatment, and at the end of study treatment.

After completion of study treatment, patients are followed periodically for up to 3 years.

PROJECTED ACCRUAL: A total of 488 patients will be accrued for this study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2006
Est. primary completion date May 2006
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed stage IV breast cancer at primary diagnosis or at recurrence

- Any T, any N, M1

- At least 1 dominant osteolytic or osteoblastic or mixed metastatic lesion outside any prior radiation field

- Lesion measures = 1.0 cm by x-ray, CT scan, and/or MRI

- Controlled asymptomatic brain metastases allowed

- Controlled bone pain, defined as a physician/health care provider rating of = grade 2 pain-SELECT (Bone) on the NCI CTC for Adverse Events Version 3.0 rating scale, required

- Current evidence of vertebral or nonvertebral fractures or spinal compression due to cancer, as determined by the treating physician, allowed

- No Paget's disease of the bone

- Estrogen receptor (ER) or progesterone receptor (PR) status known

PATIENT CHARACTERISTICS:

- Female patient

- Menopausal status not specified

- Zubrod performance status 0-2

- Creatinine normal

- Creatinine clearance = 60 mL/min

- Serum calcium < 12 mg/dL

- Not pregnant or nursing

- Fertile patients must use effective contraception

- Must be able to receive IV medication and oral medication (i.e., must have physical integrity of the upper gastrointestinal tract)

- No malabsorption syndrome

- No primary hyperparathyroidism

- No known history of aspirin-sensitive asthma

- No other prior malignancy except for the following:

- Adequately treated basal cell or squamous cell skin cancer

- In situ cervical cancer

- Adequately treated stage I or II cancer currently in complete remission

- Any other cancer for which the patient has been disease-free for at least 5 years

- No uncontrolled medical illness or infection, including, but not limited to, the following:

- Unstable angina

- Recent myocardial infarction

- Life-threatening cardiac arrhythmia

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior bisphosphonates for metastatic bone disease

- More than 28 days since prior aminoglycoside antibiotics

- At least 28 days since prior oral bisphosphonates for osteoporosis

- More than 6 months since prior bisphosphonates used for adjuvant therapy

- Concurrent treatment, including chemotherapy, hormonal therapy, and/or biologic therapy for metastatic breast cancer allowed

- No concurrent participation in another clinical treatment trial for this cancer unless the patient is no longer receiving the intervention and is in the follow-up phase of the other clinical trial

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Intervention

Drug:
ibandronate

zoledronate

Procedure:
quality-of-life assessment


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Southwest Oncology Group National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Skeletal-related events (SRE)
Secondary Change in patient's rating of worst pain as measured by the Brief Pain Inventory
Secondary Survival and time to first clinically apparent SRE
Secondary Tolerability and toxicity as measured by NCI CTCAE v3.0
Secondary Changes in performance status
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A